MediciNova Gets Orphan Drug Tag for Glioblastoma Med

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation to MN-166 (ibudilast) as adjunctive therapy to temozolomide  for the treatment of glioblastoma (GBM).

Yuichi Iwaki, MD, PhD, President and Chief Executive Officer of MediciNova, Inc., commented, “We are very pleased that the FDA has granted orphan-drug designation for MN-166 as adjunctive therapy to temozolomide for the treatment of GBM, a rare cancer with a high recurrence rate and poor prognosis.”

https://globenewswire.com/news-release/2018/10/04/1617208/0/en/MediciNova-Announces-FDA-Grants-Orphan-Drug-Designation-to-MN-166-ibudilast-for-Glioblastoma.html